WO2008027442A3 - Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use - Google Patents

Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use Download PDF

Info

Publication number
WO2008027442A3
WO2008027442A3 PCT/US2007/019015 US2007019015W WO2008027442A3 WO 2008027442 A3 WO2008027442 A3 WO 2008027442A3 US 2007019015 W US2007019015 W US 2007019015W WO 2008027442 A3 WO2008027442 A3 WO 2008027442A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid agonists
pharmaceutical formulations
oral pharmaceutical
abuse deterrent
agonists
Prior art date
Application number
PCT/US2007/019015
Other languages
French (fr)
Other versions
WO2008027442A2 (en
Inventor
Najib Babul
Original Assignee
Theraquest Biosciences Llc
Najib Babul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraquest Biosciences Llc, Najib Babul filed Critical Theraquest Biosciences Llc
Publication of WO2008027442A2 publication Critical patent/WO2008027442A2/en
Publication of WO2008027442A3 publication Critical patent/WO2008027442A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to pharmaceutical compositions of opioid agonists and the use thereof for preventing or minimizing the risk of abuse and/or toxicity due to opioid agonists and any co-abused cannabinoid agonists or alcohol from either intentional or unintentional tampering. The present invention is also directed at methods of preventing or minimizing the risk of abuse and/or toxicity due to opioid agonists and any co-abused cannabinoid agonists or alcohol from either intentional or unintentional tampering.
PCT/US2007/019015 2006-08-30 2007-08-30 Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use WO2008027442A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84097006P 2006-08-30 2006-08-30
US60/840,970 2006-08-30
US84899406P 2006-10-04 2006-10-04
US60/848,994 2006-10-04

Publications (2)

Publication Number Publication Date
WO2008027442A2 WO2008027442A2 (en) 2008-03-06
WO2008027442A3 true WO2008027442A3 (en) 2008-10-16

Family

ID=39136569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019015 WO2008027442A2 (en) 2006-08-30 2007-08-30 Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use

Country Status (1)

Country Link
WO (1) WO2008027442A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
EP2224915A4 (en) * 2007-12-17 2014-01-22 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224806A4 (en) * 2007-12-17 2014-02-19 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20110097395A1 (en) * 2008-03-08 2011-04-28 Najib Babul Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
US20090246256A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
AR073361A1 (en) * 2008-09-05 2010-11-03 Gruenenthal Gmbh PHARMACEUTICAL COMBINATION THAT INCLUDES 3 - (- 3-DIMETHYLAMINE-1-ETIL-2-METHYL-PROPYL) -PHENOL AND AN ANTIEPILEPTICO. USE
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
ES2586439T3 (en) * 2008-09-18 2016-10-14 Purdue Pharma Lp Pharmaceutical dosage forms comprising poly (E-caprolactone)
CA2741984C (en) * 2008-10-30 2018-06-12 Gruenenthal Gmbh Novel and potent tapentadol dosage forms
ES2414856T3 (en) 2008-12-12 2013-07-23 Paladin Labs Inc. Narcotic drug formulations with decreased addiction potential
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
GB201020895D0 (en) * 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
MX355760B (en) 2010-12-13 2018-04-27 Salix Pharmaceuticals Inc Gastric and colonic formulations and methods for making and using them.
CN102210764B (en) * 2011-05-30 2013-04-17 陕西师范大学 Application of sweet almond oil in preparing medicament for treating myocardial ischemia reperfusion injury
CN102526353B (en) * 2012-03-15 2015-12-16 山东金诃药物研究开发有限公司 A kind of preparation method for the treatment of the drug combination preparation of myocardial ischemia
EP2877161A1 (en) 2012-07-06 2015-06-03 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
PT2877163T (en) 2012-07-27 2019-05-24 Redhill Biopharma Ltd Formulations and methods of manufacturing formulations for use in colonic evacuation
EP2890367A4 (en) * 2012-08-29 2016-03-30 Salix Pharmaceuticals Inc Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
RU2673818C2 (en) * 2012-11-30 2018-11-30 Экьюра Фармасьютикалз, Инк. Self-regulated release of active pharmaceutical ingredient
CN105164245B (en) 2013-02-08 2018-05-22 通用磨坊公司 Low-sodium diet
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3116509B1 (en) 2014-03-12 2022-06-22 The Trustees of Columbia University in the City of New York A new class of mu-opioid receptor agonists
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CN104324311A (en) * 2014-09-22 2015-02-04 陈英娣 Traditional Chinese medicine for treatment of multiple sclerosis
EP3209282A4 (en) * 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3229785A2 (en) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxone monopreparation and multi-layer tablet
ES2922976T3 (en) * 2015-05-13 2022-09-22 4P Pharma Apomorphine for the treatment of methylphenidate-induced hyperactivity
US9827282B2 (en) * 2015-07-24 2017-11-28 Bao Tran Medication dispensing system
JP2019524655A (en) 2016-06-29 2019-09-05 キャンサイエンス イノベーションズ インコーポレーテッドＣａｎｎｓｃｉｅｎｃｅ Ｉｎｎｏｖａｔｉｏｎｓ Ｉｎｃ． Decarbonized cannabis resin, its use, and process for producing it
EP3600320A4 (en) * 2017-03-31 2020-12-16 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceuticals ingredients
US11439595B2 (en) * 2018-07-18 2022-09-13 Glatt Gmbh Immediate release formulations of cannabinoids
CA3140813A1 (en) * 2019-06-13 2021-12-07 Imbucanna, Inc Compressible cannabinoid pharmaceutical composition
CA3155260A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods for reducing rewarding effects of morphine without affecting its analgesic effects
CN112759670B (en) * 2020-12-17 2022-03-15 中国石油大学(华东) Mussel bionic functionalized hydrophilic polymer and hydrophilic polymer network modified super-hydrophilic net membrane as well as preparation method and application thereof
CN113265436A (en) * 2021-06-07 2021-08-17 南京中医药大学 Method for efficient biotransformation of anthraquinone products from traditional Chinese medicine sources by using streptomyces coeruleorubidus DM

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy
US20030073714A1 (en) * 2001-08-06 2003-04-17 Christopher Breder Opioid agonist formulations with releasable and sequestered antagonist
US20030143269A1 (en) * 2000-02-08 2003-07-31 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US20030143269A1 (en) * 2000-02-08 2003-07-31 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy
US20030073714A1 (en) * 2001-08-06 2003-04-17 Christopher Breder Opioid agonist formulations with releasable and sequestered antagonist
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same

Also Published As

Publication number Publication date
WO2008027442A2 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
WO2008027442A3 (en) Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
WO2008021394A3 (en) Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A3 (en) Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
WO2008024408A3 (en) Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2007087452A3 (en) Abuse resistant and extended release formulations and method of use thereof
WO2008033351A3 (en) Multimodal abuse resistant and extended release formulations
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008013838A3 (en) Pyridizinone derivatives
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2008049116A3 (en) Substituted indoles
WO2007136439A3 (en) Hyperpolarization methods, systems and compositions
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008010921A3 (en) Modulators of pharmacokinetic properties of therapeutics
WO2007109178A3 (en) Indole derivatives as inhibitors of histone deacetylase
WO2007054623A3 (en) Mammalian hedgehog signaling inhiabitors
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
WO2008127275A3 (en) Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
IL197941A0 (en) Use of anilinopyrimidine derivatives for the preparation of pharmaceutical compositions for treating non-alcoholic liver diseases
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837500

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07837500

Country of ref document: EP

Kind code of ref document: A2